Tracery Technology

While Dry AMD is a complex disease of innate immunity, oxidative stress, and lipid dysregulation, the only thing that can be measured as a clinical trial endpoint is the is the size of a patch of damage, limiting stratification of patients. Furthermore, standard Fundus Autofluorescence (FAF) can only measure tissue after it is lost, limiting prevention studies.

The measures of disease for Dry AMD are inadequate, limiting and complicating clinical trial design. This is evidenced by numerous clinical trial failures, and absence of a treatment on the market.

There is an enormous need for better biomarkers and measures of disease.

To address this need, Tracery is developing a novel ocular imaging acquisition method and large data analytics platform for centralized, cloud-based analysis of structured and unstructured health data.


Our technology can:

1. Detect & quantify more disease

2. Detect disease earlier

3. Identify new phenotypes

4. Predict disease progression

5. Detect immune cells in the eye



* Enhanced patient phenotyping

* Combined IMAGE-based and GENOMICS-based companion and complementary biomarker development

* Improved clinical trial design and drug development in complex ophthalmic diseases


Clinical Trials

Dr. Shelley Boyd runs Canada’s only High-Risk dry AMD Clinic. All studies are carried out at the ophthalmology Patient Education & Research Centre (Eye-PERC) established by Dr. Boyd, and in conjunction with St. Michael’s Hospital. The clinic focuses on patient education, risk modification and research.

State of the art imaging equipment allows us to carefully describe the stage of dry AMD and to further identify your particular phenotypes of disease. This information is vital for correlating subtypes of dry AMD against possible underlying causes and risk of progression.

1) Role of inflammation in AMD and other retinal disorders: Using Tracery’s imaging method to take specialized images of patient eyes, looking for sites of active inflammation. Results from this study are helping understand the role of innate immunity in AMD and other ophthalmic disorders.

2) Dry AMD Registry: Enrols patients referred with a diagnosis of high-risk dry AMD and wishing to participate in our research registry. These patients may ultimately be selected to participate if any new studies are initiated.

3) Four-field OCT as a potential screening tool for Reticular Pseudodrusen (RPD): RPD are a special subtype of dry AMD that carry an especially high risk of progression. We specifically evaluate patients for the presence of RPD and use a modified photographic process to look in regions of the retina where RPD are known to occur.

Physician Referral Form

Information for Patients

All patients must be referred by their own eye care specialist

Information for Referring Physicians

Download referral form